Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch

Soleno Therapeutics (SLNO) reported strong initial sales for its FDA-approved drug VYKAT XR, generating $32.7 million in net product revenue for Q2 2025, its first quarter of sales, and significantly reducing its net loss to $4.7 million. The company demonstrated robust commercial traction with 646 patient start forms and secured over $500 million in liquidity, including a recent $230 million capital raise, while also submitting a Marketing Authorization Application for European approval. Despite an 81.6% YTD stock return and positive analyst price targets, InvestingPro analysis suggests the stock is currently trading above its Fair Value.

Analysis

Soleno Therapeutics (SLNO) has demonstrated a highly successful commercial launch for its Prader-Willi syndrome treatment, VYKAT XR, generating $32.7 million in net product revenue in its first quarter of sales. This robust initial uptake, evidenced by 646 patient start forms from 295 unique prescribers, has materially improved the company's financial profile, narrowing its quarterly net loss to $4.7 million from $21.9 million year-over-year. The company has fortified its balance sheet significantly, ending the quarter with $293.8 million in cash and subsequently raising an additional $230 million in gross proceeds in July, creating a strong liquidity position to fund expanded commercial activities and a potential European launch. The submission of a Marketing Authorization Application to the European Medicines Agency represents a key catalyst for future growth. While the stock has seen a substantial 81.6% year-to-date return, supported by analyst price targets ranging from $97 to $145, an InvestingPro analysis indicates the stock may be trading above its fair value, introducing a note of caution regarding its current valuation.

Key Decisions for Investors

• Investors should view the strong initial sales figures and broad prescriber adoption of VYKAT XR as a significant de-risking event, validating the drug's commercial potential in the U.S. market.
• Despite the operational success and an 81.6% YTD stock price increase, the current valuation warrants scrutiny, as analysis suggests the stock is trading above its fair value, potentially indicating that near-term growth is already priced in.
• The company's strong capital position of over $500 million post-offering secures funding for its U.S. rollout and European expansion efforts, making the European Medicines Agency's decision on VYKAT XR a critical upcoming catalyst to monitor.